ホーム › 急性骨髄性白血病 › ネブラスカ州 › Omaha
Omaha、NEにおける急性骨髄性白血病の臨床試験
Omahaとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する10件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9マイル先
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- Children's Hospital and Medical Center of Omaha, Omaha
- University of Nebraska Medical Center, Omaha
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- University of Nebraska Medical Center, Omaha
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
被験者募集中第2/3相
- University of Nebraska Medical Center, Omaha
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University of Nebraska Medical Center, Omaha
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
被験者募集中第1/2相
- Nebraska Cancer Specialists, Omaha
- University of Nebraska Medical Center, Omaha
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Baldwin Park, CA40件の研究
- Seattle, WA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA30件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Omahaにおける他の研究
- 前立腺がん27件の研究
- 非小細胞肺癌24件の研究
- 乳がん22件の研究
- 大腸癌18件の研究
- がん（全種類）18件の研究
- 多発性骨髄腫16件の研究
- 非ホジキンリンパ腫14件の研究
- 卵巣がん14件の研究
- 膵臓がん14件の研究
- 頭頸部扁平上皮癌13件の研究
- 心不全13件の研究
- 転移性癌13件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。